Risk factors for nonadherence to warfarin: results from the IN-RANGE study
- PMID: 18271059
- PMCID: PMC2919157
- DOI: 10.1002/pds.1556
Risk factors for nonadherence to warfarin: results from the IN-RANGE study
Abstract
Background: Warfarin is widely used to prevent stroke and venous thromboembolism despite its narrow therapeutic window. Warfarin nonadherence is a substantial problem, but risk factors have not been well elucidated.
Methods: A prospective cohort study of adults initiating warfarin at two anticoagulation clinics (University and VA-affiliated) was performed to determine factors affecting nonadherence to warfarin. Nonadherence, defined by failure to record a correct pill bottle opening each day, was measured daily via electronic medication event monitoring systems (MEMS) caps. A multivariable explanatory model using logistic regression for longitudinal data was used to identify risk factors for nonadherence.
Results: One hundred eleven subjects were followed for a median of 137 days. Warfarin nonadherence was common (4787 of 22,425 or 21% of patient-days observed). Factors independently associated with higher odds of nonadherence included education beyond high school (odds ratio (OR) 1.8 (95%CI 1.2-2.7)), lower Short Form (SF)-36 mental component score (OR 1.4 (1.1-1.6) for each 10 point decrease); and impaired cognition (< or =19 points) on the Cognitive Capacity Screening Examination (CCSE) (OR 2.9 (1.7-4.8)). Compared to currently employed subjects, unemployed (OR 0.6 (0.3-1.2)) and retired (OR 0.5 (0.3-0.8)) subjects had somewhat improved adherence; disabled subjects over age 55 had worse adherence (OR 1.8 (1.1-3.1)) than younger disabled subjects (OR 0.8 (0.4-1.5)).
Conclusions: Poor adherence to warfarin is common and risk factors are related to education level, employment status, mental health functioning, and cognitive impairment. Within the carefully controlled anticoagulation clinic setting, such patient-specific factors may be the basis of future interventions to improve nonadherence.
Figures
Similar articles
-
Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.Chest. 2010 Apr;137(4):883-9. doi: 10.1378/chest.09-0039. Epub 2009 Nov 10. Chest. 2010. PMID: 19903973 Free PMC article.
-
Nonadherence with INR monitoring and anticoagulant complications.Thromb Res. 2013 Aug;132(2):e124-30. doi: 10.1016/j.thromres.2013.06.006. Epub 2013 Jun 22. Thromb Res. 2013. PMID: 23800635
-
The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.Arch Intern Med. 2007 Feb 12;167(3):229-35. doi: 10.1001/archinte.167.3.229. Arch Intern Med. 2007. PMID: 17296877
-
Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study.J Gen Intern Med. 2007 Sep;22(9):1254-9. doi: 10.1007/s11606-007-0233-1. Epub 2007 Jun 22. J Gen Intern Med. 2007. PMID: 17587092 Free PMC article.
-
Practical management approaches to anticoagulation non-compliance, health literacy, and limited English proficiency in the outpatient clinic setting.J Thromb Thrombolysis. 2011 Apr;31(3):321-5. doi: 10.1007/s11239-011-0560-2. J Thromb Thrombolysis. 2011. PMID: 21337118 Review.
Cited by
-
A call for action to include psychosocial management into holistic, integrated care for patients with atrial fibrillation.Europace. 2024 Mar 30;26(4):euae078. doi: 10.1093/europace/euae078. Europace. 2024. PMID: 38533841 Free PMC article.
-
How drug onset rate and duration of action affect drug forgiveness.J Pharmacokinet Pharmacodyn. 2024 Jun;51(3):213-226. doi: 10.1007/s10928-023-09897-1. Epub 2024 Jan 10. J Pharmacokinet Pharmacodyn. 2024. PMID: 38198076
-
Lower-adherence direct oral anticoagulant use is associated with increased risk of thromboembolic events than warfarin.J Interv Card Electrophysiol. 2024 Jun;67(4):709-718. doi: 10.1007/s10840-023-01585-x. Epub 2023 Aug 9. J Interv Card Electrophysiol. 2024. PMID: 37556090
-
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry.J Clin Med. 2022 Aug 18;11(16):4845. doi: 10.3390/jcm11164845. J Clin Med. 2022. PMID: 36013082 Free PMC article.
-
Challenges of Anticoagulation Management Service and Need of Establishing Pharmacist-Led Anticoagulation Clinic in Tertiary Care Teaching Hospital, Ethiopia: A Qualitative Study.J Multidiscip Healthc. 2022 Apr 6;15:743-754. doi: 10.2147/JMDH.S359558. eCollection 2022. J Multidiscip Healthc. 2022. PMID: 35418756 Free PMC article.
References
-
- Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy; Chest; 2004. pp. 204S–233S. - PubMed
-
- Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. - PubMed
-
- The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5–10. - PubMed
-
- Kimmel SE, Chen Z, Price M, et al. The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (IN-RANGE) study. Arch Intern Med. 2007;167:229–235. - PubMed
-
- Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
